| Mar'20 | Dec'19 | Sep'19 | Jun'19 | Mar'19 | Dec'18 | Sep'18 | Jun'18 | Mar'18 | Dec'17 | Sep'17 | Jun'17 | Mar'17 | Dec'16 | Sep'16 | Jun'16 | Mar'16 | Dec'15 | Sep'15 | Jun'15 | Mar'15 | Dec'14 | Sep'14 | Jun'14 | Mar'14 | Sep'13 | Dec'12 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Operating expenses: | ||||||||||||||||||||||||||
Research and development | ||||||||||||||||||||||||||
57,659 | 61,640 | 53,538 | 52,251 | 48,668 | 62,255 | 43,355 | 33,387 | 28,460 | 24,771 | 20,598 | 18,296 | 17,541 | 13,474 | 18,802 | 12,991 | 11,247 | 16,231 | 8,113 | 11,507 | 5,767 | 6,114 | 4,241 | 2,110 | 2,981 | 1,134 | 241 |
Research and development costs paid to Amgen | ||||||||||||||||||||||||||
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1,066 | - | 550 | - |
In-process research and development license acquired from MSK | ||||||||||||||||||||||||||
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 3,018 |
General and administrative | ||||||||||||||||||||||||||
17,038 | 18,059 | 19,018 | 23,284 | 19,223 | 19,561 | 16,865 | 19,236 | 13,992 | 11,031 | 11,062 | 9,613 | 8,620 | 5,280 | 7,140 | 6,494 | 5,814 | 5,539 | 4,146 | 3,601 | 3,544 | 5,548 | 1,708 | 1,358 | 4,096 | 868 | 834 |
Total operating expenses | ||||||||||||||||||||||||||
74,697 | 79,699 | 72,556 | 75,535 | 67,891 | 81,816 | 60,220 | 52,623 | 42,452 | 35,802 | 31,660 | 27,909 | 26,161 | 18,754 | 25,942 | 19,485 | 17,061 | 21,770 | 12,259 | 15,108 | 9,311 | 10,596 | 5,949 | 4,534 | 7,077 | 2,552 | 4,093 |
Loss from operations | ||||||||||||||||||||||||||
-74,697 | -79,699 | -72,556 | -75,535 | -67,891 | -81,816 | -60,220 | -52,623 | -42,452 | -35,802 | -31,660 | -27,909 | -26,161 | -18,754 | -25,942 | -19,485 | -17,061 | -21,770 | -12,259 | -15,108 | -9,311 | -10,596 | -5,949 | -4,534 | -7,077 | -2,552 | -4,093 |
Interest and other income, net | ||||||||||||||||||||||||||
1,188 | 1,215 | 661 | 1,207 | 1,634 | 1,757 | 1,859 | 1,743 | 1,009 | 473 | 564 | 481 | 509 | 519 | 576 | 605 | 503 | 522 | 380 | 163 | 153 | 66 | 30 | 23 | 6 | 3 | - |
Loss before provision for income taxes | ||||||||||||||||||||||||||
- | - | -71,895 | -74,328 | - | - | -58,361 | -50,880 | - | -35,329 | -31,096 | -27,428 | -25,652 | -18,235 | -25,366 | -18,880 | -16,558 | -21,248 | -11,879 | -14,945 | -9,158 | -10,530 | -5,919 | -4,511 | -7,071 | -2,549 | -4,093 |
Provision for (benefit from) income taxes | ||||||||||||||||||||||||||
- | - | 0 | 0 | - | - | 0 | 3 | - | -16 | 0 | 0 | 2 | 0 | 7 | 0 | 3 | 0 | -11 | 0 | 2 | -3 | 0 | 0 | -22 | -13 | 17 |
Net loss | ||||||||||||||||||||||||||
-73,509 | -78,496 | -71,895 | -74,328 | -66,257 | -80,012 | -58,361 | -50,883 | -41,443 | -35,313 | -31,096 | -27,428 | -25,654 | -18,235 | -25,373 | -18,880 | -16,561 | -21,248 | -11,868 | -14,945 | -9,160 | -10,527 | -5,919 | -4,511 | -7,049 | -2,536 | -4,110 |
Other comprehensive (loss) gain: | ||||||||||||||||||||||||||
Unrealized (loss) gain on available-for-sale securities | ||||||||||||||||||||||||||
-16 | -13 | 60 | 135 | 378 | 109 | 56 | 19 | -373 | -63 | 26 | 38 | 31 | -218 | -158 | 142 | 569 | -569 | 117 | -48 | 82 | -89 | -11 | 11 | -11 | - | - |
Other comprehensive gain (loss) | ||||||||||||||||||||||||||
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -11 | 11 | -11 | - | - |
Comprehensive loss | ||||||||||||||||||||||||||
-73,525 | -78,509 | -71,835 | -74,193 | -65,879 | -79,903 | -58,305 | -50,864 | -41,816 | -35,376 | -31,070 | -27,390 | -25,623 | -18,453 | -25,531 | -18,738 | -15,992 | -21,817 | -11,751 | -14,993 | -9,078 | -10,616 | -5,930 | -4,500 | -7,060 | -2,536 | -4,110 |
Net loss per common share: | ||||||||||||||||||||||||||
Basic and diluted net loss per common share | ||||||||||||||||||||||||||
-1.20 | -1.32 | -1.31 | -1.60 | -1.44 | -1.78 | -1.29 | -1.15 | -1.05 | -1.16 | -1.02 | -0.94 | -0.88 | -0.63 | -0.88 | -0.66 | -0.58 | -0.77 | -0.43 | -0.62 | -0.42 | 7.53 | -4.20 | -3.37 | -5.58 | -2.59 | -5.60 |
Weighted-average shares outstanding used to calculate basic and diluted net loss per common share | ||||||||||||||||||||||||||
61,208 | 57,762 | 54,920 | 46,426 | 46,124 | 45,863 | 45,406 | 44,379 | 39,596 | 30,675 | 30,474 | 29,247 | 29,056 | 28,920 | 28,801 | 28,665 | 28,542 | 28,514 | 27,675 | 24,224 | 21,918 | -1,393,163 | 1,410,507 | 1,337 | 1,263 | 977 | 733 |